Document is current

Article History

Received: 29 September 2023

Accepted: 7 November 2024

First Online: 16 November 2024

Declarations

:

: The Age-Well RCT was approved by the ethics committee (<i>Comité de Protection des Personnes</i> CPP Nord-Ouest III, Caen; trial registration numbers: EudraCT: 2016–002441-36; IDRCB: 2016-A01767-44; ClinicalTrials.gov Identifier: NCT02977819). All participants gave their written informed consent to the study prior to enrollment.

: Not applicable.

: Independent of this work, AGC is an unpaid sub-investigator or principal investigator in Alzheimer’s disease clinical trials: NCT04867616 (UCB Pharma), NCT04241068 (Biogen), NCT05310071 (Envision), NCT03446001 (TauRx Therapeutics), NCT03444870 (Roche), NCT04374253 (Roche), NCT04777396 (Novo Nordisk), NCT04777409 (Novo Nordisk), NCT04770220 (Alzheon), NCT05423522 (Medesis Pharma).GC reported grants, personal fees and non-financial support from <i>Institut National de la Santé et de la Recherche Médicale</i> (Inserm), grants from European Union’s Horizon 2020 Research and Innovation program under grant agreement No 667696 (PI), grants from <i>Fondation d’entreprise MMA des Entrepreneurs du Futur</i>, during the conduct of the study; personal fees from <i>Fondation Entrepreneurs MMA</i>, grants and personal fees from <i>Fondation Alzheimer</i>, grants from <i>Région Normandie</i>, grants from <i>Fondation Recherche Alzheimer</i>, grants from <i>Association France Alzheimer</i>, outside the submitted work.GP has received research support from the European Union’s Horizon 2020 Research and Innovation program under grant agreement No 667696, from the <i>Institut National de la Santé et de la Recherche Médicale</i> (Inserm) and from <i>Région Normandie</i>.GP, GC participated to the DSMB of the Age-Well trial and to the ExCom of Medit-Ageing.No other disclosures were reported.